Deyuan Pharmaceutical (832735)： Pyroglitazone hydrochloride tablets may be expected to pass the consistency evaluation
Deyuan Pharmaceutical (832735): Pyroglitazone hydrochloride tablets may be expected to pass the consistency evaluation
In the first half of the year, the company realized net profit attributable to its mother of approximately 23.92 million yuan, an annual increase of approximately 8.
48%: Deyuan Pharmaceutical’s 2019 Interim Report shows that the company has achieved a total sales revenue of about 1.
520,000 yuan, an increase of 11% in ten years; net profit attributable to mothers was approximately 23.92 million yuan, an increase of 8 in ten years.
The company’s technical strength is maximized, and dimethylbisbutyl chloride sustained-release tablets have passed the consistency evaluation.
The company has obtained 18 patents, including 12 invention patents and 1 utility model patent.
Metylene Naphthalene Hydrochloride Sustained 深圳桑拿网 Release Tablets (0.
5g) In November 2018, the first company in China to pass the consistency evaluation of the quality and efficacy of generic drugs.
Deyuan Pharmaceutical is the first pharmaceutical company in China to declare the consistency evaluation of pyrroglitazone hydrochloride tablets: On February 13, 2019, the State Drug Administration (NMPA) replaced the company’s declared pyrroglitazone hydrochloride tablets (30mg)Application for consistency evaluation, after querying the data of the consistency evaluation information published by the Drug Evaluation Center (CDE) of the State Drug Administration, as of June 30, 2019, there has not been any other company applying for consistency evaluation for this variety.Review process.
Pyrroglitazone hydrochloride tablets (30mg) are thiazolidinediones (TZDs) insulin sensitizers used in the treatment of type 2 diabetes, which reduce blood glucose mainly by increasing the sensitivity of target cells to the action of insulin.
The company’s leading product is pyrroglitazone chloride tablets. In 2017, 2018 and the first half of 2019, the sales of pyrroglitazone hydrochloride tablets accounted for 62%, 53% and 45% of the company’s operating income, respectively.
With reference to the company’s technical level (metaphthalene hydrochloride sustained-release tablets have passed the consistency evaluation), the company’s pyrrolidone hydrochloride tablets may be expected to pass the consistency evaluation.
The company has completed pyrrolidine dione biguanide tablets (15mg / 500mg), which is a compound preparation consisting of thiazolidinediones (TZDs) and biguanides, for the treatment of type 2 diabetes.
Both thiazolidinediones, pyrrolizone and metformin, reduce insulin resistance. However, the two have different mechanisms of action and differences in the role of each other. Pyrrolizone mainly promotes glucose in metabolic tissues (skeletal muscle) and can be used for type 2Insulin resistance in diabetes, and metformin mainly inhibits liver glucose output, so the combination of the two, the effect is concentrated on metabolic defects, the anti-diabetic effect can be enhanced, thereby achieving better blood glucose control than metformin alone, while reducing the hypoglycemiaIncidence, a synergistic effect.
The original manufacturer of pioglitazone metformin tablets is Takeda Pharmaceutical Co., Ltd., which was approved by the FDA in August 2005.
At present, only Deyuan Pharmaceuticals and Sino-US East China Pharmaceuticals have listed this product.
At present, the company is compiling the application information, and will soon report the consistency evaluation of pioglitazone dimethylbisbutyl tablets.
Investment suggestion: The company’s net cash flow from operating activities is maintained at a good level, with an annual increase of 62.
The company’s R & D expenses were 1764.
40,000 yuan, an annual increase of 15.
In the latest closing, the company can continue to be 8.
8 yuan, the market value is 4.
10,000 yuan, the current market value corresponds to 19 years of PE about 10.
28X, the estimated level is lower than A-share generic drug companies (16?
17X), it is recommended to pay attention.
Risk reminders: R & D risks, risks of pyrrolidone hydrochloride review progress not meeting expectations, competition risks, policy risks